New! Sign up for our free email newsletter.
Science News
from research organizations

Two studies could lead to new personalized therapies for lung cancer patients

Date:
September 13, 2012
Source:
Cell Press
Summary:
Lung cancer is a leading cause of death worldwide and is associated with very low survival rates. Two new genome-sequencing studies have uncovered novel genes involved in the deadly disease, as well as striking differences in mutations found in patients with and without a history of smoking. The findings could pave the way for personalized therapies that boost survival rates.
Share:
FULL STORY

Lung cancer is a leading cause of death worldwide and is associated with very low survival rates. Two new genome-sequencing studies have uncovered novel genes involved in the deadly disease, as well as striking differences in mutations found in patients with and without a history of smoking. The findings, published Sept. 13 by Cell Press in the journal Cell, could pave the way for personalized therapies that boost survival rates.

"These efforts should spur more studies to fully understand the genomic landscape of lung cancer -- more specifically, those who have no history of tobacco smoking," says study author Ramaswamy Govindan of Washington University School of Medicine. "This will help us to identify new targets for therapy to improve the outcomes of our cancer patients."

Lung cancer kills more than 1.3 million people each year, and the five-year survival rate is only about 16%. Although smoking is a major risk factor for the disease, a large percentage of these patients have no history of smoking. Past studies have suggested that different types of cancer patients, including smokers and non-smokers, may have different sets of mutations that could affect how well they respond to drug treatments.

In one of the new studies, a team led by Richard Wilson of Washington University School of Medicine sequenced the genomes of tumors from patients with non-small cell lung cancer (NSCLC) -- the most common type of lung cancer. They found that the mutation rate was more than ten times higher in tumors from smokers than in those from non-smokers with NSCLC, and these two groups had different sets of mutations. Moreover, the researchers revealed mutations that could be responsible for triggering the disease and identified changes in 54 genes that could be targeted with existing drugs.

The second study, which was led by Matthew Meyerson of the Broad Institute and focused on a subtype of NSCLC called lung adenocarcinoma, also found different patterns of mutations in tumors from smokers compared with those from non-smokers and revealed mutations in genes never before implicated in cancer. "This is the largest genomic study of lung adenocarcinoma to date," says study author Alice Berger of the Broad Institute. "Our results are a testament to the power of large-scale next-generation sequencing technology to expand our understanding of tumor biology."


Story Source:

Materials provided by Cell Press. Note: Content may be edited for style and length.


Journal References:

  1. Ramaswamy Govindan, Li Ding, Malachi Griffith, Janakiraman Subramanian, Nathan D. Dees, Krishna L. Kanchi, Christopher A. Maher, Robert Fulton, Lucinda Fulton, John Wallis, Ken Chen, Jason Walker, Sandra McDonald, Ron Bose, David Ornitz, Donghai Xiong, Ming You, David J. Dooling, Mark Watson, Elaine R. Mardis, Richard K. Wilson. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers. Cell, 2012; 150 (6): 1121 DOI: 10.1016/j.cell.2012.08.024
  2. Marcin Imielinski, Alice H. Berger, Peter S. Hammerman, Bryan Hernandez, Trevor J. Pugh, Eran Hodis, Jeonghee Cho, James Suh, Marzia Capelletti, Andrey Sivachenko, Carrie Sougnez, Daniel Auclair, Michael S. Lawrence, Petar Stojanov, Kristian Cibulskis, Kyusam Choi, Luc de Waal, Tanaz Sharifnia, Angela Brooks, Heidi Greulich, Shantanu Banerji, Thomas Zander, Danila Seidel, Frauke Leenders, Sascha Ansén, Corinna Ludwig, Walburga Engel-Riedel, Erich Stoelben, Jürgen Wolf, Chandra Goparju, Kristin Thompson, Wendy Winckler, David Kwiatkowski, Bruce E. Johnson, Pasi A. Jänne, Vincent A. Miller, William Pao, William D. Travis, Harvey I. Pass, Stacey B. Gabriel, Eric S. Lander, Roman K. Thomas, Levi A. Garraway, Gad Getz, Matthew Meyerson. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell, 2012; 150 (6): 1107 DOI: 10.1016/j.cell.2012.08.029

Cite This Page:

Cell Press. "Two studies could lead to new personalized therapies for lung cancer patients." ScienceDaily. ScienceDaily, 13 September 2012. <www.sciencedaily.com/releases/2012/09/120913123221.htm>.
Cell Press. (2012, September 13). Two studies could lead to new personalized therapies for lung cancer patients. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2012/09/120913123221.htm
Cell Press. "Two studies could lead to new personalized therapies for lung cancer patients." ScienceDaily. www.sciencedaily.com/releases/2012/09/120913123221.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES